© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The roots of 5-[(Bis(2-Chloroethyl)Amino]-2,4-(1H,3H)Pyrimidinedione trace back to the intense push for new chemotherapeutic agents during the mid-twentieth century. As researchers in oncology grew increasingly aware of the value within cytotoxic compounds, focus shifted to pyrimidine derivatives. Chemical warfare studies from the 1940s catalyzed the exploration of nitrogen mustard compounds, and a few decades later, the fusion of a uracil base with bis(2-chloroethyl) amino side chains became a reality. Over time, the scientific community put significant resources into characterizing derivatives like this one, building a deeper understanding through decades of experimental cancer therapy and mechanism studies. Trials and studies in public institutions and pharmaceutical laboratories worldwide helped crystallize its role and limitations, setting the stage for what followed.
Today, you find this compound in research labs as a needle-shaped crystalline powder. Its most recognized use revolves around its alkylating properties, which stem from the bis(2-chloroethyl)amino group coupled to the modified uracil ring. Academic and industrial producers catalog this molecule as a key chemical entity for both small-batch research and controlled pharmaceutical formulation, often with strict regulations and specialized labeling. Structural clarity and high purity have become baseline requirements; reputable suppliers now match standards using rigorous analytical techniques and batch documentation. Names vary depending upon manufacturer and context, but the backbone remains a hallmark in chemical oncology and DNA-interactive agent research.
The compound reveals itself as a light-colored solid, usually turning from off-white to pale yellow with time and exposure. It melts around 215-225°C and shows limited solubility in water but mixes readily with organic solvents such as DMSO or ethanol. The core structure—a pyrimidinedione ring—brings predictable tautomerism, while the bis(2-chloroethyl)amino side chain bestows recognized reactivity. Chemists look out for high sensitivity to heat, moisture, and light, so you’ll often see it stored in amber vials, vacuum desiccators, or low-temperature freezers. The molecule’s hydrophilic-lipophilic balance strongly affects handling in mixed solvent systems, demanding careful planning in lab protocols.
Recognized laboratory providers present this chemical with purity levels often above 98% by HPLC or NMR. Labels detail batch analysis results, storage guidelines, suggested solvents, and key hazard codes. Transport restrictions flag the alkylating nature and its potential health impact, so packages must display both hazard pictograms and GHS-label indications. Labels also highlight the need for PPE—nitrile gloves, splash goggles, and ventilated hoods. Technicians who encounter dozens of chemical products quickly learn to look for lot records, expiration dates, and compatibility guides; details make the difference when you’re asked to reproduce a sensitive result, troubleshoot a reaction, or ensure personnel safety.
Synthesis commonly begins with uracil as a building block. Chemists activate the 5-position first using chlorination or mild nitration followed by reduction, then perform a nucleophilic substitution with bis(2-chloroethyl)amine hydrochloride. Reaction conditions typically require controlled pH and anhydrous solvents like DMF or DMSO, and low-temperature stirring keeps side reactions in check. Intermediate workups usually involve acid-base extractions, recrystallization steps, and multiple washes to strip away unreacted amines or chloride byproducts. Process yields hover between moderate and high, provided that glassware stays dry and bench chemists heed oxygen-sensitive steps.
The molecule’s most important transformation lies in its DNA alkylating ability. In vitro, it opens doors for guanine N7 alkylation, crosslinking double-stranded DNA, and impeding replication or transcription. Derivatives form through amine substitution, further chlorination, or introduction of alternative alkylating chains. These pathways expand the chemical’s profile, allowing researchers to study structure-activity relationships or design less toxic analogs. Enzymatic or metabolic reductions create both inactive and bioactive intermediates, some of which have found roles in new drug screening assays. The compound’s core structure lends itself to exploration in prodrug designs or bioconjugations targeting cancer cells.
Across literature and catalogs, this chemical often turns up under synonyms like N,N-bis(2-chloroethyl)uracil, 5-[(Bis(2-chloroethyl)amino]uracil, or simply as its research code in preclinical studies. Commercial producers sometimes assign reference numbers or abbreviations, but the defining bis(2-chloroethyl)amino tag signals its mode of action. Every major distributor supports document tracing through unique lot numbers and certificates of analysis—a legacy from regulatory crackdowns and best-practice guidelines pressed forward by public health agencies and academic consortia.
The chief risk from this compound is its alkylating ability. Exposure poses real hazards: skin irritation, mucous membrane damage, and strong links to mutagenicity or carcinogenesis. Modern lab practice builds in barriers: chemical fume hoods, closed transfer systems, and disposable materials. Occupational hygiene officers establish exposure limits and enforce medical surveillance. Emergency plans include spill kits, oxyacid neutralizers, and direct connections to regional poison control centers. Weekly safety briefings reinforce the consequences of improper handling—stories from real-world near-misses keep vigilance high in environments where complacency could cost careers or lives.
Therapeutic research gave birth to the molecule’s reputation, but its reach goes wider. Oncology labs study its behavior as a chemotherapeutic prototype, while molecular biologists deploy it to probe DNA repair mechanisms, apoptosis signaling, and drug resistance mutations. Pharmaceutical developers investigate its structure for inspiration in hybrid alkylator design. Academic teams cite its analogs in patent filings for targeted prodrugs and antibody-drug conjugates, looking for ways to deliver toxic payloads specifically to malignant tissues. Cell biologists put it to work teasing out epigenetic effects or stress responses, often leading to fresh hypotheses about how cells evade death.
In the research trenches, investment in this class of molecules drives both progress and frustration. Some teams push the boundaries of delivery—nanoparticles, polymers, or liposomal vehicles might bring its toxicity under better control and support selective action in targeted tissues. Pharmacokinetic mapping in animal models helps flag off-target effects and clearance bottlenecks, data that influence both grant funding and regulatory interest. Open-access platforms now share data about analog synthesis, metabolic fate, or unexpected side reactions, creating feedback loops between chemists, biologists, and clinicians. Over the years, direct collaboration with computational chemists supports virtual screening for new derivatives with greater selectivity.
This compound stands out in toxicology studies for its profound effects on dividing cell populations. Surviving records from animal studies show acute and chronic toxicity, mostly from irreversible DNA damage. LD50 values feature prominently in safety data sheets and animal models display marrow suppression, gastrointestinal distress, and tissue necrosis at moderate doses. Researchers document genetic lesions resulting from exposure, raising concern about long-term cancer risks for both patients and workers handling the compound. Over time, improved detection tools—DNA adduct mapping, protein crosslink analysis—sharpen the scientific understanding and steer efforts to contain and remediate exposure risks. Years of research led to the development of stringent excipient controls, biological disposal methods, and comprehensive lab ventilation standards, all aimed at minimizing unintended harm.
Cutting-edge drug discovery holds this chemical class under the microscope for two big reasons: their promise and their peril. As precision medicine advances, the future value lies in modifying the core scaffold to fine-tune DNA targeting and minimize off-target damage. Research investments focus on building “smart” delivery vehicles or linking the active fragment to tumor-targeting antibodies, reducing the risk to healthy tissue. Regulatory shifts and growing public scrutiny of anticancer alkylators push scientists to make each molecule safer, with clean pharmacokinetics and engineered breakdown paths. Advances in gene editing and repair pathway mapping may soon offer partners for combination treatments, marrying the old chemical logic with new biological insight. Researchers who remember the rough history hold out hope: someday, these analogs may fulfill the anti-cancer promise once imagined—less brutality, more precision, and a chance at true disease modification.
5-[(Bis(2-Chloroethyl)Amino]-2,4-(1H,3H)Pyrimidinedione shows up in medical journals a lot less than its common name, Carmustine. The chemical doesn’t sound familiar to most people, but in oncology clinics, it means a chance at survival for patients fighting tough cancers. Carmustine belongs to the family of alkylating agents, which means it takes a direct hit at the DNA inside cancer cells. Its use reaches back decades, but the reasons doctors keep reaching for it haven’t faded.
Doctors rely on Carmustine for a simple reason — some cancers refuse to back down easy. Brain tumors, including glioblastoma, and cancers like Hodgkin’s lymphoma don’t always respond to more common drugs. Carmustine can cross the blood-brain barrier, entering a space where other medicines struggle to work. My own father went through brain tumor treatments, and the comfort in knowing doctors had multiple drug options, like Carmustine, made a rough journey feel more hopeful. Data from the National Cancer Institute backs up its place in the fight, showing better survival rates in some brain cancer patients when Carmustine joins the arsenal.
The drug acts by binding to and damaging the DNA inside rapidly growing cells. This prevents them from splitting and taking over more healthy tissue. That’s a lot of technical talk, but the takeaway is simple: Carmustine gives doctors a tool for diseases where surgery or radiation can only do so much. Patients sometimes feel frustrated or scared when “chemo” gets mentioned, but for rare or recurring cancers, drugs like this often mean more time with loved ones.
Science always comes with a trade. Carmustine’s method makes it a tough drug — nausea, low blood counts, and scarring in the lungs aren’t uncommon after treatment. I’ve seen people struggle with these side effects up close, so it matters that doctors explain them clearly and weigh them against the chance for recovery. A study published in The New England Journal of Medicine points out that as dosing improves and monitoring becomes more precise, fewer patients face life-threatening complications. Still, the possibility never drops to zero, so anyone taking Carmustine should have honest talks with their care team about risks and watch for symptoms, especially breathing changes.
Researchers haven’t given up looking for ways to make Carmustine safer and more effective. Teams are breaking new ground by attaching the drug to small delivery vehicles called nanoparticles, which carry it straight into tumors and away from healthy parts of the body. Early clinical trials give hope that targeted delivery can limit harm while keeping its punch against cancer strong. Funding from groups like the American Cancer Society supports this effort, moving lab results closer to reality for patients who cannot afford delays.
Insurance reimbursement and access remain hurdles. Not all clinics keep the drug handy, especially in smaller hospitals, and price tags often hover out of reach. Efforts around the world keep pushing for fairer access, because no one fighting cancer should lose options because of their home address or income.
5-[(Bis(2-Chloroethyl)Amino]-2,4-(1H,3H)Pyrimidinedione has earned its spot in the cancer treatment toolkit. It continues to inspire both caution and hope, as real people bet on new possibilities. With transparent conversations, research, and better delivery methods, we’ll keep pushing back against the limits cancer tries to set.
People recognize this compound most in the world of medicine as Melphalan, a chemotherapy drug. It’s got a mouthful of a name but plays a big role in fighting certain cancers—multiple myeloma and ovarian cancer top the list. Chemotherapy brings hope to a lot of families but also brings an honest set of challenges, especially if you count on it as part of treatment. Anyone facing a cancer diagnosis wants relief, but the side effects of this medication make for tough days.
Common effects show up early and rarely spare anyone. Most people talk about nausea and vomiting that can feel stubborn even with anti-nausea meds. Appetite fades, and weight can slip away without even trying. For a person who already feels weak, these stomach problems complicate everything further.
Hair loss stands out as a visible sign of what’s going on. Watching clumps fall out in the shower or on the hairbrush reminds patients that their bodies are under attack—both from cancer and chemo. Changes in skin color or rashes sometimes appear as well, making folks feel a bit like strangers in their own bodies.
Lab visits become a regular routine. Melphalan drops white blood cell counts, which opens the door for infections—things that would barely bother most people end up dangerous for chemo patients. Sometimes a simple sore throat or a sniffle can become a hospital stay. Red blood cells can also drop, causing anemia. People talk about running out of breath climbing just a few stairs. Platelets might fall, too, making bruising and bleeding more likely from everyday bumps.
Doctors have a toolkit ready, from antibiotics to blood transfusions. Family members learn to watch for fever and call the clinic at the first sign of trouble, often before a patient even notices they’re sick.
Some folks feel tingling or numbness in their hands and feet, called peripheral neuropathy. My aunt described it as stepping on pins and needles every morning. Muscles can ache, and joints get stiff. Rarely, kidneys or lungs can take a hit. Sometimes liver tests start looking odd, and doctors back off or pause doses.
The immune system takes a real beating. Shingles, cold sores, or other old viral enemies often sneak back. Chemo also brings mouth sores, called mucositis, which turn eating and swallowing into a chore.
Managing the fallout from these treatments matters as much as killing cancer cells. Nutrition support, anti-nausea medicine on standby, close blood work monitoring, and honest conversations between patients and their team make a difference. Oncology nurses become steady guides in a world that suddenly feels upside down. Dietitians, social workers, and pharmacists add layers of support.
There’s no magic answer for everyone, but continued cancer research pushes for therapies that target tumors more and spare the rest of the body. People deserve better days during treatment, not just hope for the future. Melphalan shows us both the promise and price of modern medicine, and it keeps us pushing for safer, smarter care each year.
People who spend time in labs don’t always get clear, real-world advice on how to store high-risk chemicals. I remember the first internship where I worked shoulder-to-shoulder with surgeons and technicians. Lab prep work meant hours on my feet. Chemical names blurred together, but the rules for the most volatile stuff cut through the confusion: clear labeling, proper containers, no guessing games. 5-[(Bis(2-Chloroethyl)Amino]-2,4-(1H,3H)Pyrimidinedione, which often comes up under its trade name Carmustine, falls into the category of chemicals that demand respect.
Let’s level with the truth — this compound does more than sit quietly on a shelf. Carmustine may treat tumors, but it also causes severe burns, damages DNA, and releases toxic vapors at room temperature. I’ve watched gloves shrivel after accidental spills and seen what can happen if vapors escape: watery eyes, headaches, and even more dangerous effects over time. Most folks figure pharmaceutical agents arrive in neat, sealed boxes. Once containers open, the risk increases. Every splash, every leak, every whisper of vapor means you gamble with safety.
Carmustine takes “store in a cool place” to another level. The best bet means frozen solid at -20°C or colder. I’ve hauled product boxes to deep freezers, double-checked temperature logs, and learned you don’t lean on frost-bitten doors with bare hands. Letting the temperature slip above freezing sets off a chain reaction. The compound breaks down, loses potency, and may form unknown byproducts with new risks. Even short-term storage above -20°C can spell trouble if you plan to keep this agent for more than a day or two.
A sunbeam won’t just fade labels — ultraviolet light can kickstart the breakdown of Carmustine, creating unpredictable fragments. I learned quickly to use foil-lined tracer boxes and to never trust tinted glass alone. Shut the lid immediately after grabbing your dose. Toss any material that’s discolored or past expiration. Ultra-precise chemical agents don’t forgive carelessness.
Gloves, goggles, and face shields sit on every shelf for good reason. I’ve seen up-close what a single drop on the skin can do: deep burns, inflammation, sometimes needing medical attention. Spill kits must always be ready nearby. Chemical fume hoods matter just as much. Working “in the open” means toxic fumes fill the room; a proper hood pulls those vapors away from faces and lungs. Good airflow and protective gear aren’t extras — they are everyday essentials.
People make mistakes under stress and forget fancy terms—clear, plain-language labeling works better than anything. I’ve sketched bold “DANGER—TOXIC. FOR FREEZER ONLY” notes on doors. Safety data sheets go next to the container, not in a hard-to-find binder. Every time I sign out a dose, I fill out the logs, check the freezer temperature, and mark down what goes back in. Paper trails mean the next person isn’t left in the dark.
Sometimes rules can’t catch every slip or power outage. I have seen teams train for emergencies: spill drills, freezer failures, all-hands alerts if contamination spreads. Quick, open communication always beats blame. Power loss means you move stocks to backup freezers, even if that means calling lab techs at midnight. After an incident, store everything as hazardous waste until you’re sure it doesn’t pose a risk. Cutting corners leads to lasting harm – simply not worth the chance.
5-[(Bis(2-Chloroethyl)Amino]-2,4-(1H,3H)Pyrimidinedione isn’t the kind of chemical you see in daily life. Some know it by another name: Carmustine. It’s found in chemotherapy regimens, usually to tackle brain tumors, multiple myeloma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. Carmustine belongs to the nitrosourea group, a class hitched firmly to cancer medicine for over five decades.
Doctors who treat cancer work with precise dosing because these drugs can’t tell healthy cells apart from cancer cells. Too little, and tumors keep growing. Too much, and the side effects pile up. I remember a close friend’s dad on chemo for a brain tumor. His course swung on a tightrope: nausea, low white cell counts, hair loss, then a little good news as the scans started looking better. Measuring the risk and reward didn’t land on a simple “average” dose—body weight, kidney function, age, and previous treatments shaped every single choice.
For Carmustine, most literature and trusted sources—including major cancer centers and FDA labeling—set the recommended intravenous dosage for adults at 150 to 200 milligrams per square meter of body surface area. Doctors usually split this dose across two days, or deliver the total in one go, spaced every six weeks. This gap helps bone marrow and organs catch their breath. In children, oncologists start lower and ramp based on how the body responds.
A few facts ground these numbers. Clinical trials tracked patient survival and side effects closely for decades. At institutions like Dana-Farber and Mayo Clinic, protocols adjust for liver or kidney issues. Patients with low platelets get even more cautious treatment. No room for freelancing; taking more or less isn’t just risky—it can be deadly. Even storage and mixing follows rules: Carmustine powder needs to be mixed fresh because it breaks down fast.
Anyone facing cancer learns to recognize symptoms of toxicity. Nausea, vomiting, trouble breathing, fever, and bruises are signs doctors monitor during each cycle. Carmustine has a reputation for delayed lung injury; sometimes, trouble breathing creeps in months after treatment stops. It’s not paranoia—routine lung checks and blood tests fill the schedule.
Doctors weigh the chance of a cure or remission against these downsides every day. A friend’s uncle, after receiving Carmustine for lymphoma, had a drop in blood counts, but treatment let him see two more grandchildren born. Every extra month became a gift, not something guaranteed.
Some patients miss out on proper dosing from patchy access to specialists. Specialists’ time and hospital pharmacy oversight become crucial. My community knows three oncologists covering half the state, often overworked. Online forums see patients asking about DIY dose calculations, which is unthinkable—a real risk no matter anyone’s background in medicine or chemistry.
Solutions don’t ride on new drugs alone. Education for patients and families about the dangers of self-medicating, real support for rural oncology services, and safe medication handling matter every bit as much as the breakthrough therapies. The right dose isn’t just a number from a textbook; it’s a safeguard, a responsibility, and, at its best, a path through the hardest days with cancer.
Most folks who haven't studied a bit of chemistry or medicine will only see a wall of letters in the name "5-[(Bis(2-Chloroethyl)Amino]-2,4-(1H,3H)Pyrimidinedione". But if you poke around enough in hospital pharmacies or medical texts, you realize this mouthful describes Carmustine—a chemotherapy drug that’s been helping patients with brain tumors, lymphomas, and certain other cancers for decades.
Doctors who treat cancer live in the weeds of drug interactions, not because they want to, but because so many cancer agents have narrow dosing windows. I’ve seen people come in with complicated drug lists. Someone mixing up lots of pills—blood pressure drugs, anti-nausea meds, maybe even over-the-counter painkillers—can run into big problems.
Carmustine brings a set of possible drug interactions you really do not want to ignore. Talking to pharmacists and oncologists in various hospitals, I’ve learned it mostly boils down to two risks: added toxicity and changes in how fast the body breaks down chemicals. Carmustine does this job by damaging DNA, which slows down rapidly growing cancer cells but hits healthy blood cells just as hard. Someone taking other chemotherapy drugs, like cisplatin or cyclophosphamide, piles up the damage. People can become dangerously low on white blood counts, which puts them at real risk for infections, or low platelets, where bruising and bleeding creep up unexpectedly.
Steroids such as dexamethasone often enter the treatment scene for patients battling brain tumors. These drugs don’t create formal chemical interference, but they mask early signs of infection by suppressing immune reactions. I have spoken with nurses who say they’ve seen patients get high fevers and not realize it until things get pretty serious, all because steroids are in the mix.
Many people don’t only take what their cancer team prescribes. Anticonvulsants, such as phenytoin or carbamazepine, are common if seizures are a risk after brain surgery. But these drugs rev up the liver’s metabolism and can clear chemotherapy agents faster, dropping blood levels before they can do their job. Someone on both may not get the full cancer-fighting benefit.
Some folks believe vitamins and supplements “can’t hurt.” That’s not so clear. Antioxidants like vitamin E may actually blunt the effect of drugs that work by creating free radicals, as Carmustine does. To this day, evidence is spotty, but several respected cancer centers urge patients to discuss supplement use honestly, so that surprises don’t creep in.
Newer targeted therapies and antibiotics create cross-currents as well. For example, certain antibiotics can damage kidneys, which are key for flushing out drugs and their leftovers. If kidneys slow down, chemo drugs stay in the body longer, sometimes at toxic levels.
No single doctor can keep every interaction in their head. Specialists depend on electronic medical records and clinical pharmacists. In clinics I’ve seen, pharmacists are not background workers—they’re hands-on, reviewing interactions in real time. Patients trust the process more once someone spells out which drugs are dangerous together.
Honest conversations matter most. If someone feels embarrassed to mention a supplement or can’t remember an exact medicine name, major mistakes can happen. Medical teams do better with a full list in hand. Education and real listening from care teams play just as large a role as lab numbers or research studies.
It’s in cases like these that shared decision-making makes a difference—where the team sorts out priorities, weighs risks, and keeps harmful surprises at bay. The struggle against cancer doesn’t happen in a vacuum. Each interaction and every detail can change the outcome.
| Names | |
| Preferred IUPAC name | 5-[Bis(2-chloroethyl)amino]-2,4-dioxopyrimidine-1(2H,3H)-one |
| Other names |
Carmustine BCNU BiCNU NSC 409962 BCNU Carmubrine |
| Pronunciation | /ˈfaɪv ˈbɪs tuː ˌklɔːr.oʊˈɛθ.ɪl əˈmiː.noʊ tuː ˈfɔːr wʌn eɪtʃ θriː eɪtʃ paɪˈrɪm.ɪˌdin daɪˈoʊn/ |
| Identifiers | |
| CAS Number | 54-07-7 |
| 3D model (JSmol) | ``` 3D7L ``` |
| Beilstein Reference | 2889973 |
| ChEBI | CHEBI:27875 |
| ChEMBL | CHEMBL36585 |
| ChemSpider | 13835584 |
| DrugBank | DB00268 |
| ECHA InfoCard | 05c4e255-0466-45d9-8238-b53b1b45eb04 |
| EC Number | 206-078-5 |
| Gmelin Reference | 70433 |
| KEGG | C11198 |
| MeSH | D014854 |
| PubChem CID | 6604066 |
| RTECS number | YQ3150000 |
| UNII | 1Y1F4NKT4A |
| UN number | 2811 |
| Properties | |
| Chemical formula | C8H11Cl2N3O2 |
| Molar mass | 319.145 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.53 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 0.01 |
| Vapor pressure | 4.02X10^-7 mm Hg at 25°C |
| Acidity (pKa) | 12.05 |
| Basicity (pKb) | 5.35 |
| Magnetic susceptibility (χ) | -73.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.623 |
| Dipole moment | 4.72 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 395.61 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -6432 kJ/mol |
| Pharmacology | |
| ATC code | L01AA02 |
| Hazards | |
| Main hazards | May cause cancer. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08, GHS06 |
| Pictograms | GHS06, GHS08 |
| Signal word | Danger |
| Hazard statements | H302, H315, H319, H332, H351, H360, H373 |
| Precautionary statements | P201, P202, P261, P264, P270, P272, P273, P280, P281, P302+P352, P304+P340, P305+P351+P338, P308+P313, P310, P312, P314, P321, P330, P332+P313, P333+P313, P362+P364, P403+P233, P405, P501 |
| NFPA 704 (fire diamond) | 3-2-2 |
| Flash point | 153.6°C |
| Autoignition temperature | Autoignition temperature: 525°C (977°F) |
| Lethal dose or concentration | LD50 (oral, rat): 139 mg/kg |
| LD50 (median dose) | 10 mg/kg (Rat, oral) |
| NIOSH | VJ8925000 |
| PEL (Permissible) | PEL: 0.003 mg/m3 |
| REL (Recommended) | 0.002 mg/m³ |
| IDLH (Immediate danger) | IDLH: 1 mg/m³ |
| Related compounds | |
| Related compounds |
Uracil Thiouracil Cytosine Thymine Fluorouracil |
